Urolog. pro Praxi, 2008; 9(6): 302-306

Urgency and inkontinence of urine and possibilities of their farmacological treatment

MUDr. Martina Poršová1, MUDr. Ivan Kolombo FEBU2, MUDr. Jaroslav Porš3, et al
1 Urologické oddělení, Klaudiánova nemocnice, Mladá Boleslav
2 Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha
3 Urologická ambulance Městské nemocnice Turnov

Lower urinary tract symptoms (LUTS) include voiding symptoms, storage and postvoiding symptoms. Seriousness of LUTS and their impact on the quality of life can be evaluated by using lots of different questionaires. Storage symptoms – urgency and urgent incontinence and frequent voiding have most serious influence on the quality of life. Anticholinergics effecting muscarinic receptors can be used to their farmacological treatment.

Keywords: lower urinary tract symptoms, voiding symptoms, storage symptoms, overactive bladder, interstitial cystitis, perception of symptoms, bother score, anticholinergics

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Poršová M, Kolombo I, Porš J, al E. Urgency and inkontinence of urine and possibilities of their farmacological treatment. Urol. praxi. 2008;9(6):302-306.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manage Care 2000; 6(Suppl 11): 580-590.
    2. Halaška M, Dorschner W, Frank M. Treatment of urgency and incontinence in elderly patients with propiverine hydrochloride. Neurourol Urodyn 1994; 13: 428-430.
    3. Hofner K, Halaska M, Primus G, et al. Tolerability and efficacy of trospium chloride in long term treatement (52 weeks) in patients with urge syndrome: a double-blind controlled, multicentre clinical trial. Neurourol Urodyn 2000; 19: 487-488.
    4. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 5-26. Go to original source... Go to PubMed...
    5. Kim Y, Yoshimura N, Masuda H, et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2006; 97(2): 400-403. Go to original source... Go to PubMed...
    6. Krhut J. Hyperaktivní močový měchýř. Praha: Maxdorf, 2007.
    7. Martan A, a kol. Inkontinence moči u žen. Praha: Jessenius Maxdorf, 2005.
    8. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine - a new bladder selective antimuscarinic agent. Eur J Pharmacol 1997; 327: 195-207. Go to original source... Go to PubMed...
    9. Nosková P. Léčba bolesti u intersticiální cystitidy. Urolog. pro Praxi, 2008; 9(3): 112-115.
    10. Patrick DL, Chiang YP. Meassurement of health outcomes in treatment effectiveness evaluations: conceptual and methodical challenges. Med Care 2000; 38(Suppl 9): 114-125. Go to original source... Go to PubMed...
    11. Verner P. Benigní hyperplázie prostaty. Praha: Maxdorf, 2005.
    12. Vrtal R, Vidlák A, Študent V. Diagnostika a léčba hyperaktivního měchýře. Urolog. pro Praxi 2007; 8(5): 211-216.
    13. Zámečník L, et al. Sexuální dysfunkce u pacientů s chronickou prostatitidou/syndromem chronické pánevní bolesti. Urolog. pro Praxi 2005; 1: 23-25.
    14. Zámečník L, Hanuš T. Chronická bolest u intersticiální cystitidy. Urologické Listy, Medica 2007: 2.
    15. Zinner N, Tuttle J, Marks L. Efficasy and tolerability of darifenacin, a muscarinic M3 selective receptor agonisty (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23: 248-252. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.